These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type. Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428 [TBL] [Abstract][Full Text] [Related]
23. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related]
24. Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma. Li W; Li Y; Liu X; Wang L; Chen W; Qian X; Zheng X; Chen J; Liu Y; Lin L Front Immunol; 2023; 14():1180908. PubMed ID: 37646022 [TBL] [Abstract][Full Text] [Related]
25. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report. Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491 [TBL] [Abstract][Full Text] [Related]
26. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650 [TBL] [Abstract][Full Text] [Related]
30. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study. Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749 [TBL] [Abstract][Full Text] [Related]
31. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797 [TBL] [Abstract][Full Text] [Related]
32. Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis. Zhang AB; Zhang JY; Liu YP; Wang S; Bai JY; Sun LS; Li TJ J Oral Pathol Med; 2024 Jul; 53(6):393-403. PubMed ID: 38777565 [TBL] [Abstract][Full Text] [Related]
33. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration. Hirschhorn A; Campino GA; Vered M; Greenberg G; Yacobi R; Yahalom R; Barshack I; Toren A; Amariglio N; Rechavi G J Tissue Eng Regen Med; 2021 Dec; 15(12):1155-1161. PubMed ID: 34599642 [TBL] [Abstract][Full Text] [Related]
34. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305 [TBL] [Abstract][Full Text] [Related]
35. The importance of BRAF-V600E mutation to ameloblastoma metabolism. Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334 [TBL] [Abstract][Full Text] [Related]
37. Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma. Kunmongkolwut S; Chaisuparat R Int J Oral Maxillofac Surg; 2022 Aug; 51(8):1034-1042. PubMed ID: 34998647 [TBL] [Abstract][Full Text] [Related]
38. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
39. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433 [TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]